Key facts
- This page summarizes Anila Lingamneni's Form 4 filing for HAEMONETICS CORP (HAE).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 21 May 2024, 17:55.
Anila Lingamneni - 17 May 2024 Form 4 Insider Report for HAEMONETICS CORP (HAE)
- Reporting relationship
- EVP, Chief Technology Officer
- Issuer ticker
- HAE
- Reported as of
- 17 May 2024
- Net transaction value
- -$33,410
- SEC form
- 4
- Accepted by SEC
- 21 May 2024, 17:55:21 UTC
- Prior SEC filing
- 17 May 2024
- Next SEC filing
- 29 May 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Thomas V. Powers, attorney-in-fact for Ms. Lingamneni
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Anila Lingamneni filed Form 4 for HAEMONETICS CORP (HAE) on 21 May 2024.
Change
- Previous filing in this sequence was filed on 17 May 2024.
- Current net transaction value: -$33,410.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
HAE
transaction
Common Stock
Tax liability
- Transaction value
- $33,410
- Shares
- -349
- Change %
- -3%
- Price
- $95.73
- Shares after
- 11,291
- Date
- 17 May 2024
- Ownership
- Direct
- Footnotes
- F1, F2
HAE
transaction
Common Stock
Award
- Transaction value
- Shares
- +3,394
- Change %
- +30%
- Price
- Shares after
- 14,685
- Date
- 17 May 2024
- Ownership
- Direct
- Footnotes
- F2, F3, F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
HAE
transaction
Derivative
Non-qualified Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +7,461
- Change %
- Price
- $0.000000
- Shares after
- 7,461
- Date
- 17 May 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 7,461
- Exercise price
- $95.73
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.
Footnote F2
This number includes unvested RSUs previously reported.
Footnote F3
The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.
Footnote F4
Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
Footnote F5
Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.